Mitochondria in the aetiology and pathogenesis of Parkinson's disease (Q37037953)

17 August 2017

1 reference

title

Mitochondria in the aetiology and pathogenesis of Parkinson's disease. (English)

1 reference

17 August 2017

0 references

1 reference

1 reference

1

Anthony H V Schapira

1 reference

17 August 2017

publication date

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

97-109

1 reference

Epidemiology of Parkinson's disease

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Genetic and environmental factors in the cause of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial membrane permeabilization in cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Complex I, iron, and ferritin in Parkinson's disease substantia nigra

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial DNA analysis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial DNA in postmortem brain from patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Point mutations of mitochondrial genome in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Absence of the mitochondrial A7237T mutation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Novel mitochondrial DNA mutations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Sequence analysis of the entire mitochondrial genome in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Identification of mitochondrial DNA polymorphisms that alter mitochondrial matrix pH and intracellular calcium dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Origin and functional consequences of the complex I defect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

An out-of-frame cytochrome b gene deletion from a patient with parkinsonism is associated with impaired complex III assembly and an increase in free radical production

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial ND5 mutations in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkin is associated with cellular vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkin enhances mitochondrial biogenesis in proliferating cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Association between early-onset Parkinson's disease and mutations in the parkin gene

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Lewy bodies and parkinsonism in families with parkin mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

How much phenotypic variation can be attributed to parkin genotype?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Hereditary early-onset Parkinson's disease caused by mutations in PINK1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

PINK1 mutations are associated with sporadic early-onset parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Novel PINK1 mutations in early-onset parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

PINK1 protein in normal human brain and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Genetic association study of PINK1 coding polymorphisms in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Clinical Spectrum of Homozygous and Heterozygous PINK1 Mutations in a Large German Family With Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

PINK1 mutations in sporadic early-onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

A heterozygous effect for PINK1 mutations in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

DJ-1 has a role in antioxidative stress to prevent cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: role of Na+/K+ ATPase

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mitochondrial disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Early-onset familial parkinsonism due to POLG mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

alpha-synuclein promotes mitochondrial deficit and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Mice lacking alpha-synuclein are resistant to mitochondrial toxins

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

LRRK2 mutations in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Clinical features of LRRK2-associated Parkinson's disease in central Norway

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Biochemical and pathological characterization of Lrrk2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The importance of LRRK2 mutations in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Oxidative stress in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Oxidative stress in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

'Rejuvenation' protects neurons in mouse models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Altered proteasomal function in sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Lack of nigrostriatal pathology in a rat model of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Proteasome inhibition and Parkinson's disease modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

The 26S proteasome: a molecular machine designed for controlled proteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Creatine and cyclocreatine attenuate MPTP neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Novel pharmacological targets for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

Treatment options in the modern management of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970327-7

7 January 2021

10.1016/S1474-4422(07)70327-7

Identifiers

DOI

1 reference

17 August 2017

1 reference